17 research outputs found

    Reliability of HES data; Internal reliability: Intra-class correlation coefficient for each comorbidity; external reliability: Proportion of agreement for the diagnosis of the index cancer between the diagnostic fields of HES and the cancer registration data, by cancer and year of diagnosis.

    No full text
    <p>Reliability of HES data; Internal reliability: Intra-class correlation coefficient for each comorbidity; external reliability: Proportion of agreement for the diagnosis of the index cancer between the diagnostic fields of HES and the cancer registration data, by cancer and year of diagnosis.</p

    Numbers and proportions of patients with comorbidities detected at selected time points through the ten years preceding laryngeal cancer diagnosis made in 2013, given three restriction windows, N = 1,789.

    No full text
    <p>Numbers and proportions of patients with comorbidities detected at selected time points through the ten years preceding laryngeal cancer diagnosis made in 2013, given three restriction windows, N = 1,789.</p

    Hazard Ratios (HR) for the effects of cancer-related<sup>*</sup> and non-cancer related<sup>*</sup> comorbidities on the overall hazard of death, laryngeal cancer patients diagnosed in England in 2013, N = 1,789.

    No full text
    <p>Hazard Ratios (HR) for the effects of cancer-related<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0172814#t004fn002" target="_blank">*</a></sup> and non-cancer related<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0172814#t004fn002" target="_blank">*</a></sup> comorbidities on the overall hazard of death, laryngeal cancer patients diagnosed in England in 2013, N = 1,789.</p

    Demographic and Pregnancy Characteristics of Cases and Controls<sup>*</sup>.

    No full text
    <p>Demographic and Pregnancy Characteristics of Cases and Controls<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0152187#t001fn002" target="_blank"><sup>*</sup></a>.</p

    Patients characteristics at study entry and crude rates of progression to death/loss to follow-up and virologic rebound by club participation.

    No full text
    *<p>Restricted to patients who had virologic suppression at study entry, n = 2517.</p>**<p>Patients who went on to enrol in a club contributed analysis time to the “not in club” group until they were enrolled in the club. There is no single point in time where characteristics of patients who enrol in clubs and other patients can be formally compared due to the progressive nature of club enrolment. Instead predictors of club participation are presented in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0056088#pone-0056088-t002" target="_blank">Table 2</a>. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0056088#pone-0056088-t001" target="_blank">Table 1</a> shows event rates since study entry to the outcome endpoint or censoring.</p><p>ART: Antiretroviral therapy; WHO: World Health Organization; CI: Confidence interval; IQR (inter-quartile range).</p
    corecore